UK markets closed
  • NIKKEI 225

    28,455.60
    +528.23 (+1.89%)
     
  • HANG SENG

    23,983.66
    +634.28 (+2.72%)
     
  • CRUDE OIL

    71.65
    +2.16 (+3.11%)
     
  • GOLD FUTURES

    1,786.10
    +6.60 (+0.37%)
     
  • DOW

    35,659.43
    +432.40 (+1.23%)
     
  • BTC-GBP

    38,055.38
    +706.64 (+1.89%)
     
  • CMC Crypto 200

    1,298.36
    -22.92 (-1.73%)
     
  • ^IXIC

    15,647.63
    +422.48 (+2.77%)
     
  • ^FTAS

    4,178.76
    +61.16 (+1.49%)
     

Global Infectious Vaccines Partnering Terms and Agreements Report 2021: Analysis by Company A-Z, Headline Value, Stage of Development at Signing, Deal Component Type, Specific Infectious Therapy Target

·4-min read

Dublin, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The "Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals.

The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2014, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2014

  • Analysis of infectious vaccines deal structure

  • Access to headline, upfront, milestone and royalty data

  • Access to over 700 infectious vaccines deal records

  • Identify the most active infectious vaccine dealmakers since 2014

  • The leading infectious vaccines deals by value since 2014

  • Includes adjuvant deals and alliances since 2014

Available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific infectious therapy target

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking
2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals
3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers
4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Infectious Vaccines deals by company A-Z
Appendix 2 - Infectious Vaccines deals by stage of development
Appendix 3 - Infectious Vaccines deals by deal type
Appendix 4 - Infectious Vaccines deals by therapy area
Appendix 5 - Deal type definitions

Companies Mentioned

  • 2A

  • ABEC

  • Aeras

  • Binex

  • BTG

  • COVAX

  • CSIRO

  • CSL

  • CVC

  • Emmes

  • EVQLV

  • Fatro

  • Halix

  • hVIVO

  • iBio

  • IHI

  • Infor

  • IQVIA

  • Lonza

  • MMS

  • MphRx

  • Novo

  • PHC

  • PPD

  • RSV

  • Saiba

  • SEEK

  • Davis

  • Vical

  • Texas A&M University

  • Korea Advanced Institute of Science and Technology

  • Aduro BioTech

For more information about this report visit https://www.researchandmarkets.com/r/uaedd7

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting